Quantum BioPharma Targets MS and Alcohol Effects with Novel Pipeline

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is developing innovative treatments for neurological disorders that affect hundreds of millions globally. The company’s pipeline targets multiple sclerosis (MS) with Lucid-MS, a patented new chemical entity that offers a fundamentally different approach from existing therapies, aiming to address the unmet needs of the estimated 2.9 million people living with MS worldwide. An ongoing imaging collaboration with Massachusetts General Hospital supports Lucid-MS’s phase 2 development, highlighting the company’s commitment to rigorous clinical research.

In addition to its MS focus, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses another significant neurological need: the cognitive and physiological impacts of alcohol consumption. The company, which is part of the Dynamic Brand Portfolio @ IBN, is leveraging its expertise to tackle two major brain disorders affecting millions, as detailed in the full article available on MissionIR’s site.

For investors, the latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. This release is disseminated on behalf of Quantum BioPharma and may include paid advertising, underscoring the company’s proactive communication strategy. With a seasoned team and a focus on cutting-edge science, Quantum BioPharma is positioning itself as a key player in the biopharmaceutical landscape, aiming to make a tangible difference for patients suffering from neurological conditions.